Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant in Heavy Drinkers with Alcohol Use Disorder
NCT06136195Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Jul 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mavoglurant in alcohol use disorder (AUD) (2 arms), sponsored by Yale University. Primary endpoints: Change in the number of drinks consumed and Change in craving for alcohol. Started Jul 2024; status: recruiting.
02
Drugs
mavoglurant
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06136195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136195.